Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Aoxing Pharmaceutical has stated that the China State Food and Drug Administration (SFDA) has granted manufacturing license to Hebei Aoxing API Pharmaceutical Company, the joint venture (JV) between Aoxing Pharma and Macfarlan Smith.
Subscribe to our email newsletter
With the manufacturing license granted, Hebei Aoxing API Pharmaceucitcal Company submitted business license application, to manufacture Naloxone Hydrochloride API product, to the China Administrative Bureau of Industry and Commerce.
Aoxing Pharma chairman and CEO Zhenjiang Yue said that they were pleased to have received notice granting them a Manufacturing License from the SFDA and remain on target to begin producing API for the Chinese market in 2011.
"We are excited to further the development process and to help address the need in accessing the appropriate quality and quantity of API for the finished dosage narcotics in China," Yue said.
Aoxing Pharmaceutical is a US incorporated specialty pharmaceutical company with its operations in China, specialising in research, development, manufacturing and distribution of a variety of narcotics and pain-management products.
Macfarlan Smith is a wholly owned subsidiary of Johnson Matthey.
In Hebei Aoxing API Pharmaceutical, Hebei Aoxing has a 51% stake, while Macfarlan Smith (Hong Kong) holds 49%.
Hebei Aoxing will initially develop eight narcotic API products for the China market but its product range could potentially exceed 30 products.